Family offices invested heavily in biotech startups in August, signaling a renewed venture capital interest in the sector. According to Fintrx, family offices made 52 direct investments in private companies last month, with approximately 20% directed toward biotech ventures. Notable deals included LifeMine Therapeutics, which secured $188 million in a Series E round featuring investment from Jeff Bezos’s Bezos Expeditions and Bill Gates’s Gates Frontier. LifeMine is harnessing artificial intelligence (AI) to develop drugs that prevent organ failure in transplant recipients.

Stanley Druckenmiller’s Duquesne Family Office remains a key player this year, backing at least four pharmaceutical or life sciences companies. In August, Duquesne participated in a $90 million Series C funding round for Epicrispr Biotechnologies, a startup focused on gene therapy for the rare muscle disorder facioscapulohumeral muscular dystrophy (FSHD). Druckenmiller has highlighted AI’s transformative potential for biotech, emphasizing its applications across drug discovery, diagnostics, and monitoring.

The surge in investment aligns with a broader rebound in biotech venture funding, with U.S. and European biopharma startups raising $12.6 billion in the first half of 2026—a five-year peak according to Silicon Valley Bank data. Despite this growth, funding is increasingly concentrated on companies with drug candidates already in clinical testing, indicating a preference for more advanced startups over early-stage ventures.

Other influential family offices also made substantial biotech investments in August. Emerson Collective, led by Laurene Powell Jobs, invested in oncology firm InduPro, Euclidean Capital, affiliated with the late Jim Simons family, backed Leal Therapeutics targeting ALS and schizophrenia, and GenHenn Capital, run by Michael Hennessy, supported Meduloc’s bone fracture implant technologies. This trend underscores the growing role of ultra-wealthy private investors in advancing healthcare innovation through targeted biotech venture capital.